Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
DUBLIN, Ireland, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy, Director...
-
DUBLIN, Ireland, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy,...
-
Better-than-expected Hospital Product revenue improves liquidity position Restructuring and other cost reduction actions on track to realize $80 to $90 million in annualized cost savings REST-ON...
-
DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that the U.S. Food and Drug...
-
DUBLIN, Ireland, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointments of Courtney Wells...
-
DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that it will host a conference...
-
DUBLIN, Ireland, June 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced it will present two posters at the...
-
DUBLIN, Ireland, June 03, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointment of Gregory J....
-
AV001 granted Priority Review PDUFA action date is September 15, 2019 DUBLIN, Ireland, May 22, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today announced that the U.S....
-
REST-ON 63% enrolled; 98 patients remain to be enrolled Jordon Dubow, M.D., appointed as Chief Medical Officer Noctiva™-related assets sold; all operational activities have ceased DUBLIN, Ireland,...